Patent ID: 11874277
Assignee: PROPHASE LABS, INC.
Field: Measurement (Instruments)
Classification: CPC C  G | IPC G

Claim 9:
10. A method of determining expression of one or more esophageal adenocarcinoma risk factors selected from ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P, LTF, CNDP2, SET and GPI in a subject, comprising (a) processing a formalin fixed paraffin embedded (FFPE) esophageal tissue sample obtained from the subject to reverse formalin cross-links by heating the FFPE esophageal tissue sample in a detergent-free buffer to generate a processed FFPE sample, (b) digesting the processed FFPE sample with trypsin to generate a trypsin-digested FFPE sample, and (c) analyzing the trypsin-digested FFPE sample with a targeted mass spectrometry assay to detect and quantify target trypsin-digest peptides corresponding to each of ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P, and at least one of LTF, CNDP2, SET and GPI wherein the target trypsin-digest peptide corresponding to ISG15 comprises an amino acid sequence of SEQ ID NO: 11 or SEQ ID NO: 12; the target trypsin-digest peptide corresponding to LTF comprises an amino acid sequence of SEQ ID NO: 54 or SEQ ID NO: 58; the target trypsin-digest peptide corresponding to CNDP2 comprises an amino acid sequence of SEQ ID NO: 20 or SEQ ID NO: 31; the target trypsin-digest peptide corresponding to DAD1 comprises an amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 9; the target trypsin-digest peptide corresponding to SET comprises an amino acid sequence of SEQ ID NO: 50; the target trypsin-digest peptide corresponding to UBE2N comprises an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5; the target trypsin-digest peptide corresponding to S100P comprises an amino acid sequence of SEQ ID NO: 67 or SEQ ID NO: 68; and the target trypsin-digest peptide corresponding to GPI comprises an amino acid sequence of SEQ ID NO: 35 or SEQ ID NO: 39, wherein each of the trypsin-digest peptides are detectable at a sufficiently high level in the trypsin-digested FFPE sample to correlate with expression of the one-or more esophageal adenocarcinoma risk factors in the subject.